Publications by authors named "I-K Penner"

Article Synopsis
  • Cognitive impairment is a significant issue in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD), with a study showing that about 21.9% of patients experience cognitive deficits, particularly in mental flexibility and attention.
  • The study involved 32 MOGAD patients and analyzed clinical factors like age and previous relapses, finding that the overall number of relapses and past episodes of acute disseminated encephalomyelitis (ADEM) were linked to increased cognitive impairment risk.
  • MRI results indicated that patients with MOGAD had reduced white and deep gray matter volumes compared to healthy controls, highlighting potential neurological damage in this condition.
View Article and Find Full Text PDF

Background: Besides demographics and clinical factors, psychological variables and brain-tissue changes have been associated with fatigue in persons with multiple sclerosis (pwMS). Identifying predictors of fatigue could help to improve therapeutic approaches for pwMS. Therefore, we investigated predictors of fatigue using a multifactorial approach.

View Article and Find Full Text PDF

Objective: To investigate the degree of synaptic plasticity in Multiple Sclerosis (MS) patients during acute relapses compared to stable MS patients and healthy controls (HCs) and to analyze its functional relevance.

Methods: Facilitatory quadripulse stimulation (QPS) was applied to the primary motor cortex in 18 acute relapsing and 18 stable MS patients, as well as 18 HCs. The degree of synaptic plasticity was measured by the change in motor evoked potential amplitude following QPS.

View Article and Find Full Text PDF

Objective: We aimed at examining the effects of a known metacognitive training in MS (MaTiMS) and its modification with an additional neuroeducational module and mindfulness-based exercises (MaTiMS-modified) on neuropsychiatric and cognitive outcomes in people with progressive multiple sclerosis (pwpMS). Exploratively, we investigated whether the modification may show an additional benefit.

Methods: Both interventions were administered in small groups of ambulatory patients.

View Article and Find Full Text PDF

Background: Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS.

Methods: Post hoc analysis of participants with aSPMS (≥ 1 relapse in 2 years before study and/or ≥ 1 T1 gadolinium-enhancing [Gd +] magnetic resonance imaging [MRI] lesions at baseline) receiving oral siponimod (2 mg/day) or placebo for up to 3 years in EXPAND.

View Article and Find Full Text PDF

Background And Purpose: Studies reporting the baseline determinants of cognitive performance and treatment effect on cognition in patients with multiple sclerosis (MS) are limited. We investigated the baseline correlates of cognition and the long-term treatment effects of fingolimod 0.5 mg once daily on cognitive processing speed and attention in patients with relapsing-remitting MS.

View Article and Find Full Text PDF

Objective: Retinal layer thickness (RLT) measured by optical coherence tomography (OCT) is considered a noninvasive, cost-efficient marker of neurodegeneration in multiple sclerosis (MS). We aimed to investigate associations of RLT with cognitive performance and its potential as indicator of cognitive status in patients with MS by performing generalized estimating equation (GEE) analyses.

Methods: In this cross-sectional study, patients with at least mild signs of cognitive impairment were examined by OCT as well as by the Brief International Cognitive Assessment for MS and tests assessing attention and executive functions (Trail Making Test [TMT] A and B).

View Article and Find Full Text PDF

Objective: To explore the hypothesis that serum neurofilament light chain (sNfL) indicative of neuroaxonal damage may improve precise disease profiling with regard to cognition and neuropsychiatric symptoms, we analyzed potential associations of sNfL levels with cognitive test scores, fatigue, depression, and anxiety.

Methods: Patients with relapsing-remitting and secondary progressive MS (SPMS) underwent an elaborated assessment including MRI, various cognitive tests, and patient-reported outcomes. We determined sNfL levels by single molecule array (Simoa) assay.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the impact of vitamin D levels, smoking, and anti-EBV antibodies on cognitive health and neuroaxonal injury in multiple sclerosis (MS) patients over 11 years.
  • Higher vitamin D levels were linked to better cognitive performance, while smoking was associated with poorer outcomes; specifically, a significant decrease in cognitive performance was observed in smokers.
  • The anti-EBV antibody levels did not show a predictive relationship for cognitive function or neuroaxonal injury, reinforcing the significance of vitamin D and smoking status in MS patient management.
View Article and Find Full Text PDF

The cerebellum is known to be involved not only in motor but also cognitive and affective processes. Structural changes in the cerebellum in relation to cognitive dysfunction are an emerging topic in the field of neuro-psychiatric disorders. In Multiple Sclerosis (MS) cerebellar motor and cognitive dysfunction occur in parallel, early in the onset of the disease, and the cerebellum is one of the predilection sites of atrophy.

View Article and Find Full Text PDF